secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001193125-25-323798
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid reports Phase 1 safety and PK for OV350; oral KCC2 activator OV4071 on track for Q1 2026 filing
--------------------------------------------------------------------------------

- OV350 IV showed good safety; no treatment-related SAEs or lab findings in 16 healthy participants.
- PK as predicted; exploratory qEEG indicated central activity consistent with KCC2 modulation.
- OV4071 (oral) is 20-fold more potent; regulatory submission for Phase 1/1b expected Q1 2026, clinical start Q2 2026.
- Company will not advance OV350 IV further; resources directed to oral KCC2 activators OV4071 and OV4041.
- Most common AE was headache; nausea/vomiting in subset attributed to off-target pharmacology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000119312525323798/0001193125-25-323798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000119312525323798/d84904d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-323798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer